21 CFR 210 and 211: A Subpart-by-Subpart Map of cGMP Requirements

21 CFR 210 and 21 CFR 211 are usually cited together — “210/211” — but they do very different jobs. Part 210 is three short sections that establish that these are the minimum current Good Manufacturing Practice (cGMP) requirements and define what counts as a “drug.” Part 211 is where the actual operational requirements live, spread across eleven subparts running from personnel qualifications to what happens to a returned or salvaged product. Most guidance treats “cGMP” as a single undifferentiated body of rules; this page maps where each specific requirement actually sits, so a specific finding, a specific SOP gap, or a specific inspection question can be traced back to the exact subpart and section range that governs it. For the broader question of what “current” adds to “GMP” as a legal concept, see CASRAI’s GMP vs. cGMP comparison — this page assumes that distinction and focuses on structure instead.

What Part 210 Actually Does

Part 210 (“Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General”) has only three operative sections, and none of them impose a facility or process requirement on their own:

• § 210.1 — Status of current good manufacturing practice regulations. States that the Part 211 (and related) regulations set out the minimum cGMP for methods, facilities, and controls; failure to meet them renders a drug adulterated under the Federal Food, Drug, and Cosmetic Act, whether or not the drug actually failed to meet its specifications. This is the section that makes cGMP violations independently actionable — a batch can pass every release test and still be adulterated if the process that made it didn’t meet Part 211.
• § 210.2 — Applicability. Establishes that where a more specific drug-category regulation exists, the more specific requirement controls if it conflicts with the general Part 211 requirement, and that Part 211’s requirements apply unless specifically derogated (the basis for FDA’s phase-appropriate GMP guidance for early-phase investigational drugs, discussed below).
• § 210.3 — Definitions. Defines the terms Part 211 relies on throughout — including batch, lot, component, in-process material, quality control unit, and drug product. Several Part 211 subparts only make sense once these definitions are read first; the definition of “quality control unit” in particular is what Subpart B’s personnel requirements are actually structured around.

In short: Part 210 is the legal scaffolding — why cGMP is enforceable and which terms mean what. Part 211 is the content.

Part 211’s Eleven Subparts, At a Glance

Part 211 is organized by functional area, not by product type or process step. The table below is the map; the sections after it go one level deeper into each subpart.

Subpart B — Organization and Personnel (§§ 211.22–211.34)

Subpart B is short but load-bearing: it’s where the quality control unit (QCU) gets its statutory teeth. § 211.22 requires a QCU with the authority to approve or reject all components, in-process material, packaging, labeling, and finished product — and to review production records before a batch is released. It is the single most frequently cited section in FDA warning letters for a reason: almost every other Part 211 failure (a missed in-process check, an unreviewed deviation, a released batch with an open investigation) ultimately traces back to a QCU that didn’t have, or didn’t exercise, that authority. § 211.25 requires that personnel have the education, training, and experience to perform their assigned functions, plus documented training in the specific CGMP requirements applicable to their job; § 211.28 covers personnel responsibilities for hygiene and health status; § 211.34 extends the same accountability to outside consultants advising on manufacturing, processing, packing, or holding.

Subpart C — Buildings and Facilities (§§ 211.42–211.58)

Subpart C sets the physical-plant requirements: suitable size and location; separate or defined areas to prevent mix-ups and cross-contamination between operations; adequate lighting and ventilation with filtration and, where needed, temperature/humidity control; potable water with no cross-connection to non-potable systems; sanitary sewage and waste disposal; and a written sanitation program covering pest control, cleaning, and maintenance. CASRAI’s cGMP Facility Requirements guide goes deep on this subpart specifically — cleanroom classification, qualification documentation, and how the requirement differs for APIs (governed instead by ICH Q7 Section 4) and for devices (governed by the QMSR rather than Part 211 at all).

Subpart D — Equipment (§§ 211.63–211.72)

Equipment must be of appropriate design, adequate size, and suitably located for its intended use, cleaning, and maintenance (§ 211.63). § 211.67 requires written procedures and schedules for cleaning and maintenance, and equipment cleanliness/use logs. § 211.68 addresses automated, mechanical, and electronic equipment, including the calibration and inspection requirements that connect this subpart to 21 CFR Part 11 for any equipment generating electronic records — see CASRAI’s 21 CFR Part 11 term for that boundary. § 211.72 covers filters used in the production of injectables, specifically prohibiting asbestos-containing filters without further downstream non-fiber-releasing filtration.

Subpart E — Control of Components and Drug Product Containers and Closures (§§ 211.80–211.94)

Every incoming component, container, and closure must be identified, sampled representatively, tested or verified against specifications, and held under quarantine status until the QCU releases or rejects it. § 211.84 sets out the sampling and testing requirements in detail, including when a supplier’s certificate of analysis can substitute for full identity testing. § 211.94 extends the same control to containers and closures themselves, since a non-conforming closure can compromise a conforming product after the fact.

Subpart F — Production and Process Controls (§§ 211.100–211.115)

This is the largest operational subpart. § 211.100 requires written production and process control procedures, reviewed and approved by the QCU, that are followed in execution and documented at the time of performance. § 211.103 requires actual yields to be calculated and compared against expected yields at each production stage, with investigation of any significant discrepancy. § 211.110 covers in-process sampling and testing to monitor and, where necessary, adjust the process. § 211.111 sets time limits on production phases where control is time-dependent. Subpart F is where “the batch record” as a document class actually originates — the requirements here are what a batch production record has to demonstrate compliance with.

Subpart G — Packaging and Labeling Control (§§ 211.122–211.137)

Covers label storage and issuance controls, 100% examination or a statistically valid sampling plan for label reconciliation before release, tamper-evident packaging requirements for OTC drugs (§ 211.132, added after the 1982 Tylenol tampering incident led to a specific FDA rulemaking), and expiration dating requirements (§ 211.137).

Subpart H — Holding and Distribution (§§ 211.142–211.150)

Requires written procedures for storage and shipment, quarantine of finished product before QCU release, storage conditions consistent with labeling, and distribution records adequate to facilitate a recall if one becomes necessary — a direct link between this subpart and any product recall procedure.

Subpart I — Laboratory Controls (§§ 211.160–211.176)

Requires scientifically sound specifications, standards, sampling plans, and test procedures for components, in-process material, and finished product. § 211.165 covers testing and release requirements, including that a finished product must meet its identity, strength, quality, and purity specifications before release. § 211.166 requires a stability testing program to support expiration dating. § 211.170 requires reserve samples of each lot to be retained. § 211.192 requires that any unexplained discrepancy or failure to meet specifications be thoroughly investigated — this is the section behind the modern “OOS investigation” (out-of-specification investigation) as a named quality process.

Subpart J — Records and Reports (§§ 211.180–211.198)

Requires that all records required by Part 211 be retained for at least one year past the expiration date of the batch (or, for OTC products without expiration dating, three years past distribution), be readily available for inspection, and in most cases be retrievable within the facility itself. § 211.180 sets the general retention framework; § 211.198 requires a written procedure for handling and investigating written and oral product complaints, with complaint records maintained regardless of whether the complaint appears well-founded on first review.

Subpart K — Returned and Salvaged Drug Products (§§ 211.204–211.208)

Covers what has to happen before a returned drug product can be reprocessed or a salvaged product can be released: identification, testing, and a documented evaluation of whether the product’s exposure (storage conditions, handling, time) makes it suitable for its labeled use. This is the subpart most often overlooked in a facility’s own procedures, precisely because returns are infrequent enough that a written procedure can go untested for years.

Why 210 and 211 Get Cited Together

An FDA Form 483 observation or a warning letter citing a Part 211 section is almost always paired, at least implicitly, with § 210.1’s framing: the specific 211 section defines what was deficient, and 210.1 is why that deficiency is independently a cGMP violation — adulteration under 21 U.S.C. § 351(a)(2)(B) — regardless of whether any specific batch tested out of specification. That’s the practical reason it’s worth knowing Part 210 exists at all, even though it never appears in an SOP title: it’s the legal basis that makes every Part 211 citation enforceable on its own, not just evidence toward a broader adulteration claim.

Phase-Appropriate GMP and the Part 211 Exemption

Not every drug subject to Part 210 is subject to the full scope of Part 211. Under § 210.2(c), most Phase 1 investigational drugs are exempt from the full Part 211 requirements, per FDA’s 2008 guidance CGMP for Phase 1 Investigational Drugs — though the statutory adulteration provisions under 21 U.S.C. § 351(a)(2)(B) still apply, and FDA’s guidance still describes facility, documentation, and materials-control expectations appropriate to Phase 1 scale. That exemption ends once a drug enters Phase 2 or 3, or once material from an earlier batch has been used in a later-phase or marketed product.

What Part 211 Does Not Cover

Part 211 governs finished human and veterinary drugs specifically. It is not the only US cGMP regulation, and mistaking it for a catch-all is a common source of confusion:

• Active pharmaceutical ingredients (APIs) are governed by ICH Q7, not Part 211 directly — ICH Q7 forms the basis of EU GMP Annex 4/EudraLex Volume 4 Part II for API manufacturing.
• Dietary supplements have their own cGMP regulation, 21 CFR Part 111, structured similarly but legally separate from Part 211.
• Medical devices fall under the Quality Management System Regulation (QMSR, effective February 2, 2026, incorporating ISO 13485:2016 by reference) rather than Part 211 — see CASRAI’s 21 CFR Part 820 guide for that regulation’s own subpart map and the QMSR transition.
• Nonclinical (preclinical) safety studies are governed by 21 CFR Part 58, Good Laboratory Practice, not Part 211 — a distinction covered in CASRAI’s GxP Compliance guide, which maps how GLP, GCP, GMP, and GDP requirements apply across different product types and study phases.

Frequently Asked Questions

What’s the difference between 21 CFR 210 and 21 CFR 211?

Part 210 is three short sections establishing that cGMP regulations set the legal minimum standard and defining the terms Part 211 uses. Part 211 is the eleven-subpart body of specific operational requirements — personnel, facilities, equipment, materials control, production, packaging, holding, laboratory controls, records, and returns — that those minimums actually consist of.

Is 21 CFR 211 the same thing as cGMP?

For finished human and veterinary drugs, yes in practice — Part 211 (read together with Part 210’s framing) is what “cGMP” refers to. But cGMP as a general concept also applies to other product types under different, related regulations: ICH Q7 for APIs, Part 111 for dietary supplements, and the QMSR for devices.

Which Part 211 subpart covers the quality control unit?

Subpart B, Organization and Personnel (§§ 211.22–211.34). § 211.22 specifically defines the QCU’s authority to approve or reject materials and finished product.

Does 21 CFR 211 apply to Phase 1 clinical trial material?

Mostly not, in full. Under § 210.2(c) and FDA’s 2008 guidance on CGMP for Phase 1 investigational drugs, most Phase 1 material is exempt from the full scope of Part 211, though facility, documentation, and materials-control expectations still apply at a scale appropriate to Phase 1, and the underlying statutory adulteration provisions remain in force.

What subpart covers out-of-specification (OOS) investigations?

Subpart I, Laboratory Controls, specifically § 211.192, which requires that any unexplained discrepancy or a batch’s failure to meet its specifications be thoroughly investigated, whether or not the batch has already been distributed.